Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Pulmonary/Respiratory Diseases | Family Medicine
 Disease Category: Lung Cancer
Location: United States, ND

Trial Information

Advanced Stage Non-small Cell Lung Cancer

Study to evaluate the long-term safety and efficacy of Darbepoetin Alfa in anemic subjects with Advanced Stage Non-small Cell Lung Cancer receiving multi-cycle chemotherapy.

Patient Inclusion Criteria:

  • Subjects with metastatic (stage IV) Non-small Cell Lung cancer, receiving or about receive first line cyclic chemotherapy, life expectancy >6 months, 18 years and older

Patient Exclusion Criteria:

  • Subjects with a history of brain metastasis, known primary benign or malignant hematologic disorder which can cause anemia, history of or current, active cancer (other than non-small lung), uncontrolled angina, uncontrolled heart failure or uncontrolled chronic cardiac arrhythmia, subject with history of a seizure disorder.

Dr. Tom Davis, Director of Business Development
Legacy Pharma Research
601 N. 5th St.
Bismarck, ND 58501
Phone: 701-751-1128
Fax: 701-751-1131
Email: tdavis.legacy@midconetwork.com

View Map

Research Center Information: Legacy Pharma Research

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.